(IN BRIEF) Sanofi has announced positive phase 2 clinical results for lunsekimig, a novel bispecific therapy targeting key inflammatory pathways in respiratory diseases. The treatment successfully met primary and key secondary endpoints in studies involving moderate-to-severe asthma and chronic rhinosinusitis … Read the full press release
Posted in Business, Financial, France, Healthcare, Industrial, Investment, Management, Marketing, Pharma & Biotech, Science, Security & Safety, Technology
Tagged asthma treatment, atopic dermatitis, biologic therapy, chronic rhinosinusitis with nasal polyps, clinical trials, CRSwNP, drug development, Houman Ashrafian, IL13, lunsekimig, Nanobody VHH, Phase 2 study, respiratory diseases, Sanofi, Sanofi Advances Respiratory Pipeline with Promising Clinical Data for Dual Targeting Lunsekimig Therapy, Sanofi Reports Positive Phase 2 Results for Lunsekimig in Asthma and Respiratory Diseases Development, TSLP
(IN BRIEF) Sanofi’s phase 3 study for its drug tolebrutinib has shown promising results in treating non-relapsing secondary progressive multiple sclerosis (nrSPMS), a condition with no current approved therapies. The HERCULES study revealed that tolebrutinib successfully delayed disability progression in … Read the full press release
Posted in France, Healthcare, Pharma & Biotech
Tagged activated microglia, annualized relapse rate (ARR), B lymphocytes, brain-penetrant BTK inhibitor, central nervous system (CNS), confirmed disability progression (CDP), Copenhagen, Denmark, disability accumulation, European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS), GEMINI 1 and 2 phase 3 studies, HERCULES phase 3 study, Houman Ashrafian, innate immunity, multiple sclerosis, neuroinflammation, non-relapsing secondary progressive MS (nrSPMS), PERSEUS phase 3 study, primary progressive MS, Sanofi, teriflunomide, tolebrutinib
(IN BRIEF) Sanofi is showcasing its ambitious pipeline transformation strategy, which includes a record 12 potential blockbuster opportunities currently under clinical evaluation. Among these, there are nine innovative medicines and vaccines with peak sales potential ranging from €2 to €5 … Read the full press release
Posted in Business, France, Healthcare, Industrial, Management, Media, News, Pharma & Biotech, Science, Technology
Tagged Houman Ashrafian, Immunology Industry, Paul Hudson, Sanofi
EuropaWire (EW) is the first truly pan-European and leading press release distribution and newswire service for Europe and the European Union working towards consolidating Europe’s voice on the global newswire and media scene. The newswire service comes with advanced submission forms, flexible pricing and PR budgeting, granular targeting, nearly uncapped reach across countries, markets, verticals, industries, audiences, languages, etc., translation and localisation for greater local PR impact, in-depth distribution reporting, metrics and insights including measured PR reach, reads, engagements, impact, etc., no cap on words, images and multimedia to go along with your release, among others. Your press releases will be seen among the releases of Europe’s biggest and most prominent companies, brands and institutions. Here you can learn more about EuropaWire’s mission, achievements, services, etc.
HOW TO GET STARTED?